Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal

被引：0
作者：
A M Vannucchi
E Antonioli
P Guglielmelli
A Pardanani
A Tefferi
机构：
[1] UF di Ematologia,Dipartimento di Area Critica Medico
[2] Università degli Studi,Chirurgica
[3] Azienda Ospedaliera-Universitaria Careggi,Division of Hematology, Department of Medicine
[4] Mayo Clinic,undefined
[5] Istituto Toscano Tumori,undefined
来源：
Leukemia | 2008年 / 22卷
关键词：
JAK2V617F mutation; myeloproliferative neoplasms; allele burden; polycythemia vera; primary myelofibrosis; essential thrombocythemia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
JAK2 and MPL mutations are recurrent in myeloproliferative neoplasms (MPNs). A JAK2 mutation, primarily JAK2V617F, is almost invariably associated with polycythemia vera (PV). However, JAK2V617F also occurs in the majority of patients with essential thrombocythemia (ET) or primary myelofibrosis (PMF) as well as in a much smaller percentage of those with other MPNs. The mechanism(s) behind this one allele-multiple phenotypes phenomenon has not been fully elucidated. The issue is further confounded by the presence of marked variation in JAK2V617F allele burden among mutation-positive patients. In the current communication, we discuss potential mechanisms for phenotypic diversity among JAK2V617F-positive MPNs as well as review the current literature in regard to genotype–phenotype correlations (that is clinical correlates and prognostic significance) in the context of both the presence or absence of the mutation (ET and PMF) and its allele burden (PV, ET and PMF).
引用
收藏
页码：1299 / 1307
页数：8
相关论文
共 438 条
  • [1] James C(2005)A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 434 1144-1148
  • [2] Ugo V(2005)Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet 365 1054-1061
  • [3] Le Couedic JP(2005)Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Cancer Cell 7 387-397
  • [4] Staerk J(2005)A gain-of-function mutation of JAK2 in myeloproliferative disorders N Engl J Med 352 1779-1790
  • [5] Delhommeau F(2007)JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis N Engl J Med 356 459-468
  • [6] Lacout C(2006)MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia PLoS Med 3 e270-3476
  • [7] Baxter EJ(2006)MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients Blood 108 3472-1646
  • [8] Scott LM(2007)Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis Exp Hematol 35 1641-4200
  • [9] Campbell PJ(2004)Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin Blood 103 4198-375
  • [10] East C(1951)Some speculations on the myeloproliferative syndromes Blood 6 372-5
12345678910